TTR and nervous system disorder: In animal models of ATTR, this duo effectivelyreduced both fibrillar and nonfibrillar deposits, and in a small phase IIopenlabel study, the combination stabilized cardiac and neurologic disease inmost treated patients over one year with an acceptable safety profile [86].Encouragingly, a larger randomized phase III trial comparing doxycycline/TUDCAplus supportive therapy versus supportive care alone (NCT03481972) is currentlyunderway [87].